title: Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.
abstract: In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell line, we established a docetaxel-resistant PC-3 cell line (DR-PC3). In DR-PC3 cells, DT therapy stronger inhibited proliferation/viability than docetaxel alone. Based on gene ontology analysis, we found versican as a selective gene. This result with the findings of cDNA microarray and validated by quantitative RT-PCR. In addition, the effect of DT therapy on cell viability was the same as the effect of docetaxel plus versican siRNA. In other words, silencing of versican can substitute for thalidomide. In the clinical setting, versican expression in prostate biopsy samples (before DT therapy) correlated with PSA reduction after DT therapy (p<0.05). Thus targeting versican is a potential therapeutic strategy in docetaxel-resistant prostate cancer.
authors: Departments of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
authors: Naoko
authors: N
authors: Arichi
authors: Departments of Urology, Shimane University Faculty of Medicine, Izumo, Japan ; Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California.
authors: Yozo
authors: Y
authors: Mitsui
authors: Departments of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
authors: Miho
authors: M
authors: Hiraki
authors: Departments of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
authors: Sigenobu
authors: S
authors: Nakamura
authors: Departments of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
authors: Takeo
authors: T
authors: Hiraoka
authors: Departments of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
authors: Masahiro
authors: M
authors: Sumura
authors: Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California.
authors: Hiroshi
authors: H
authors: Hirata
authors: Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California.
authors: Yuichiro
authors: Y
authors: Tanaka
authors: Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California.
authors: Rajvir
authors: R
authors: Dahiya
authors: Departments of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
authors: Hiroaki
authors: H
authors: Yasumoto
authors: Departments of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
authors: Hiroaki
authors: H
authors: Shiina
keywords: castration resistant prostate cancer; taxane resistance; thalidomide chemotherapy; versican